About momelotinib
JAK1/JAK2 and ACVR1 inhibitor
Used for
- Treats adults with intermediate- or high-risk myelofibrosis and anemia.
Usual adult dose
200 mg by mouth once daily; dose may be adjusted for side effects or blood counts.
Common side effects
- Low platelet or white blood cell counts
- Bacterial infections
- Dizziness
- Diarrhea
Important warnings
- Can cause serious infections, low blood counts, bleeding, liver injury, or blood clots.
- Monitor blood counts and liver tests during treatment.
- May increase risk of major cardiovascular events and certain cancers.
- Avoid live vaccines during treatment.
Pregnancy
May harm an unborn baby; pregnancy status should be checked before treatment.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least one week after the last dose.
Interactions
- Strong CYP3A4 inhibitors or inducers may affect momelotinib levels.
- Check before combining with other medicines that increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.